New MedTech for Erectile Dysfunction in Men with Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis Developed by Fine Treatment

OXFORD, UK / ACCESSWIRE / October 13, 2023 / Benign prostate enlargement, known as BPH or BPE, and chronic prostatitis are often accompanied by erectile dysfunction. It was confirmed that novel Thermobalancing therapy with Dr Allen’s Device reduces the size of enlarged prostate and helps to recover from chronic prostatitis. Now, a new clinical trial studying “The effect of Dr Allen’s Device and Thermobalancing Therapy on erectile dysfunction in men with chronic prostate diseases” registered at the World Health Organization via the ISRCTN Registry has been successfully completed.

Erectile dysfunction (ED) may occur in any man regardless of his age and race. However, ED is much more likely to develop after the age of 50. Almost half (48%) of all men in the UK say they experience difficulty getting or keeping an erection, while the overall prevalence of ED in North America is between 22-58% and the prevalence of ED is higher in Asian men compared to European men. Chronic prostatitis can cause erectile dysfunction due to inflammatory agents that are released during inflammation.

ED can also occur as a nasty side effect associated with the long-term use of medications for BPH and chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS).

Effective and safe at-home treatment with Dr Allen’s Device

The patented Thermobalancing therapy with Dr Allen’s Device is a novel out-of-hospital treatment designed for an easy at-home use. Dr Allen’s Device is registered with the British Medical Healthcare Agency, has been well tested in 5 clinical trials and during over 12 years on the market. A medical journal article sheds light on the science behind this medtech innovation: Innovative Thermobalancing therapy and Dr Allen’s Device for the first time employ body energy to treat chronic prostatic diseases effectively.

The analysis of new clinical trial data on erectile dysfunction in men with BPH or CP/CPPS shows that the novel medical technology with Dr Allen’s Device improves ED safely, without any adverse impacts, and supports overall men’s health.

What men with BPH or CP/CPPS can experience after common standard treatments

  • Long-term courses of antibiotics are prescribed to men with CP/CPPS, even when bacteria have not been confirmed, and they are sometimes given to men with BPH. Such treatment suppresses the immune system and weakens the body, and may also cause allergies and other reactions.
  • Prostate massage cannot help but can cause damage to the delicate prostate tissue, bleeding around the prostate gland, development of prostatic calculi, acute epididymitis, and other health problems.
  • Anti-inflammatory drugs, such as, diclofenac; fenoprofen; ibuprofen; indomethacin; naproxen, and others can cause stomach ulcers, heart and kidney problems.
  • Alpha blockers, such as alfuzosin, doxazosin, terazosin, tamsulosin, and prazosin, can, in the long-term, reduce the quality of life in men by causing impotence, depression, testicular swelling and pain.
  • Hormonal drugs, such as 5 alpha reductase inhibitors: finasteride, Avodart, can be responsible for irreversible side effects: impotence, depression, testicle pain, and even diabetes.
  • Antidepressant drugs may lead to constipation, which aggravates the chronic process in the affected prostate gland.
  • Prostate surgeries remove or destroy prostate tissue. All surgical interventions are associated with complications. As a result, approximately 25% of patients suffer from depression after even a minimally invasive prostate surgery.

It is precisely these multiple side effects of common standard treatments what motivated Dr Simon Allen, an experienced doctor specialising in internal medicine, to design safe Thermobalancing therapy addressing unmet patient needs. Fine Treatment makes wearable Dr Allen’s Devices accessible around the world.

About Fine Treatment

Fine Treatment is a leading Oxford-based research and development company with a patented medical technology, called Thermobalancing therapy and Dr Allen’s Devices. Totally risk-free, this non-invasive treatment is proven to be highly effective. Designed to be worn on the body, the therapeutic Dr Allen’s Devices provide a unique, life-changing treatment for various health conditions, including prostate enlargement (BPH or BPE); chronic prostatitis; kidney stone disease; chronic low back pain; upper spine stiffness; knee pain and osteoarthritis; chronic headaches; and coronary heart disease.

Contact Information:

Alex Day
Customer Services Manager, Fine Treatment
Oxford, United Kingdom
Tel: +447958878300
Email: info@finetreatment.com

SOURCE: Fine Treatment

View source version on accesswire.com:
https://www.accesswire.com/792039/new-medtech-for-erectile-dysfunction-in-men-with-benign-prostatic-hyperplasia-bph-and-chronic-prostatitis-developed-by-fine-treatment

Staff

Recent Posts

Best Testosterone Supplement For Men Over 40 and 50: Testo Prime for Muscle Growth & Libido 2025

If you are male and in your 40's and 50's and feel your testosterone levels…

23 minutes ago

The Anxiety Clinic Launches Innovative Approach to Transform Anxiety into Positive Energy

Transforming Anxiety into Positive Energy: A New Approach by The Anxiety ClinicBondi Junction, New South…

4 hours ago

Solace Psychology Announces Expanded Holiday Stress Management and Mental Health Support Services

Embracing Mental Well-Being During the Festive SeasonCarlton North, Australia--(Newsfile Corp. - December 24, 2024) -…

6 hours ago

Strong Natural Diet Pill Over the Counter for 2025 – PhenQ OTC Weight Loss Supplement

If you are researching the strongest over the counter weight loss supplements in 2025 -…

6 hours ago

Fortitude Wellbeing Enhances Mental Health Services with Comprehensive ADHD Assessments

Fortitude Wellbeing Expands Offerings with ADHD AssessmentsSouth Yarra, Australia--(Newsfile Corp. - December 24, 2024) -…

8 hours ago

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today…

9 hours ago